Compartmentalized microfluidic culture platform to study mechanism of paclitaxel-induced axonal degeneration.
Chemotherapy induced peripheral neuropathy is a common and dose-limiting side effect of anticancer drugs. Studies aimed at understanding the underlying mechanism of neurotoxicity of chemotherapeutic drugs have been hampered by lack of suitable culture systems that can differentiate between neuronal cell body, axon or associated glial cells. Here, we have developed an in vitro compartmentalized microfluidic culture system to examine the site of toxicity of chemotherapeutic drugs. To test the culture platform, we used paclitaxel, a widely used anticancer drug for breast cancer, because it causes sensory polyneuropathy in a large proportion of patients and there is no effective treatment. In previous in vitro studies, paclitaxel induced distal axonal degeneration but it was unclear if this was due to direct toxicity on the axon or a consequence of toxicity on the neuronal cell body. Using microfluidic channels that allow compartmentalized culturing of neurons and axons, we demonstrate that the axons are much more susceptible to toxic effects of paclitaxel. When paclitaxel was applied to the axonal side, there was clear degeneration of axons; but when paclitaxel was applied to the soma side, there was no change in axon length. Furthermore, we show that recombinant human erythropoietin, which had been shown to be neuroprotective against paclitaxel neurotoxicity, provides neuroprotection whether it is applied to the cell body or the axons directly. This observation has implications for development of neuroprotective drugs for chemotherapy induced peripheral neuropathies as dorsal root ganglia do not possess blood-nerve-barrier, eliminating one of the cardinal requirements of drug development for the nervous system. This compartmentalized microfluidic culture system can be used for studies aimed at understanding axon degeneration, neuroprotection and development of the nervous system.
Yang
In Hong
IH
Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Siddique
Rezina
R
Hosmane
Suneil
S
Thakor
Nitish
N
Höke
Ahmet
A
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000633:toxicity*; D001369:Axons / Q000187:drug effects / Q000473:pathology*; D002452:Cell Count / Q000379:methods; D002478:Cells, Cultured; D004622:Embryo, Mammalian; D004921:Erythropoietin / Q000627:therapeutic use; D005452:Fluoresceins; D005727:Ganglia, Spinal / Q000166:cytology; D044085:Microfluidics / Q000379:methods*; D009410:Nerve Degeneration / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control; D017239:Paclitaxel / Q000633:toxicity*; D051381:Rats; D011994:Recombinant Proteins; D011984:Sensory Receptor Cells / Q000187:drug effects*
D000972:Antineoplastic Agents, Phytogenic; D005452:Fluoresceins; D011994:Recombinant Proteins; D004921:Erythropoietin; C085925:calcein AM; D017239:Paclitaxel